Clinical evidence shows that AposHealth (an FDA-cleared medical device) improves pain, stiffness, and function in people with knee osteoarthritis.
However, it’s uncertain if these improvements are clinically meaningful. The analyses suggest that AposHealth is cost saving by £1,958 per person when compared with standard care if knee surgery is delayed for 5 years. Because the evidence for the potential cost savings is limited, further data collection is recommended to understand if cost savings are made once AposHealth is used in the NHS.
Recent Posts
PEPFAR TB Impact: Averting Millions of Cases and Deaths Among HIV Patients
PEPFAR TB Impact has been profound, with the U.S. President’s Emergency Plan for AIDS Relief averting an estimated 11.0 million tuberculosis (TB) cases and 2.1 million TB-related deaths among persons with HIV between 2003 and 2024. The PEPFAR TB impact extends far beyond HIV, delivering substa...
Vitamin B6 Depletion Risk in Carbidopa/Levodopa Therapy and Seizure Implications
Carbidopa/levodopa products used for Parkinson’s disease can cause vitamin B6 depletion risk, potentially leading to seizures. The U.S. Food and Drug Administration (FDA) has identified 14 cases of seizures linked to vitamin B6 deficiency, all occurring in patients taking levodopa doses above 1,0...
Advancing Collaborative TB Innovation to Tackle Drug Resistance
Collaborative TB Innovation is essential to ending the world’s deadliest infectious disease. Tuberculosis (TB) still claims millions of lives each year, with rising drug resistance, climate-driven migration, and conflict severely undermining global progress. While the burden falls heaviest on low...